Navigation Links
Perrigo Confirms Filing for Clobetasol Shampoo and Announcement of Patent Infringement Lawsuit by Galderma
Date:8/19/2010

ALLEGAN, Mich., Aug. 19 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for clobetasol propionate shampoo, 0.05%, and notified Galderma, the listed patent owner.

On August 17, 2010, Galderma filed suit alleging patent infringement in the United States District Court for the Northern District of Texas to prevent Perrigo from proceeding with the commercialization of this product. This action formally initiates the process under the Hatch-Waxman Act.  

The product is substitutable to Galderma's Clobex® Shampoo, 0.05%, a topical corticosteroid indicated for the treatment of moderate to severe psoriasis of the scalp. Sales for the brand were approximately $53 million, according to Wolters Kluwer data for the twelve months ending June 2010.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing reflects our razor focused strategy of bringing new extended topical products to market and making quality healthcare more affordable for our customers."  

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Confirms Filing for Generic Version of Gynazole-1® Cream and Announcement of Patent Infringement Lawsuit by KV Pharma
2. Perrigo Announces FDA Approval for Over-the-Counter Cetirizine Cherry Syrup
3. Perrigo Company Confirms Patent Challenge for Clobetasol Propionate Emulsion Foam
4. Perrigo Acquires Exclusive Sales and Distribution Rights to OTC Store Brand Versions of Allegra® and Allegra D-12 From Teva
5. Perrigo Company to Present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging and Leisure Conference
6. Perrigo Company to Present at the 31st Annual Goldman Sachs Global Healthcare Conference
7. Perrigo Announces FDA Final Approval for Miconazole
8. Perrigo Acquires Rights to Generic Version of HalfLytely® from Novel Laboratories
9. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
10. Perrigo Company Announces Quarterly Dividend
11. Perrigo Acquires Infant Formula Manufacturer PBM Holdings for $808 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2020)... ENCINITAS, Calif. (PRWEB) , ... May 27, 2020 , ... Hemp Health One’s Giving Away ... free CBD products for the next 60 days. The company is hosting the daily giveaway ... simple. Start by following Hemp Health One’s Instagram page or Hemp Health One’s Facebook page. ...
(Date:5/26/2020)... ... ... Melwood is proud to be donating thousands of vegetable and flowering plants ... and nursing homes. “It’s more important than ever to reach out to those who ... little cheer to seniors and individuals of differing abilities,” said Melwood’s President and CEO, ...
(Date:5/25/2020)... ... , ... Federal data has already confirmed that most of the deadly victims ... failing to report that many of those who have died from the virus were ... new song by an artist that calls himself The Undiscovered Artist brings light to ...
Breaking Medicine Technology:
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... ... healthcare organization is joining the clinically integrated network (CIN) and the group purchasing ... with AHN’s Cardiovascular Institute to establish a heart failure program at Mon Health ...
(Date:5/28/2020)... ... May 28, 2020 , ... With ... the fall, operators of student housing are scrambling to implement practices that will ... over 37,000 student housing beds on 38 campuses across the country, has researched ...
(Date:5/27/2020)... ... ... The podiatrists and foot doctors of Advanced Foot & Ankle Specialists are ... Arbor Michigan. Dr. Tomasz Biernacki states that “Podiatrists can help support the ... We have been seeing patients in the hospital for the past 3 months, but ...
(Date:5/27/2020)... Ore. (PRWEB) , ... May ... ... May 2020 , Guest: Dr. Gerald Pollack, University of Washington Professor of ... Phase of Water: Beyond Solid, Liquid & Vapor ( https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2 ) , ...
(Date:5/26/2020)... LIVONIA, Mich. (PRWEB) , ... ... ... and RevSpring today announced the availability of two leading RevSpring solutions—Talksoft® patient ... Loyale Patient Payment platform by engaging patients through automated and precise texts, ...
Breaking Medicine News(10 mins):